trending Market Intelligence /marketintelligence/en/news-insights/trending/kt6ilks6gjolcrqn7xtvlq2 content esgSubNav
In This List

Novartis makes executive changes; Gilead's chief scientific officer resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novartis makes executive changes; Gilead's chief scientific officer resigns

S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.

* André Wyss is stepping down as president of Novartis Operations as part Novartis AG's decision to split the unit into two separate divisions.

* Gilead Sciences Inc. said Norbert Bischofberger is stepping down as the chief scientific officer and executive vice president of research and development, effective at the end of April. He will be replaced by Gilead's executive vice president of clinical research, John McHutchison. The company's executive vice president of clinical R&D operations, Andrew Cheng, was named chief medical officer, effective in April.

* Illumina Inc. appointed Phil Febbo chief medical officer, effective March 26.

* Bruker Corp. appointed Gerald Herman its interim CFO, effective March 17. The company said Herman was appointed to replace outgoing CFO Anthony Mattacchione, who resigned in February.

* Cellectis SA named Elsy Boglioli COO after the retirement of Mathieu Simon as executive vice president and COO.

* Xenon Pharmaceuticals Inc. promoted Ian Mortimer to the position of president. Mortimer will also remain the company's CFO. Also, the biotechnology company appointed Ernesto Aycardi chief medical officer, effective March 19.

* Five Prime Therapeutics Inc. said its CFO and senior vice president, Marc Belsky, resigned to pursue another opportunity. Belsky will continue in his current role until April 6.

* Innovate Biopharmaceuticals Inc. named June Almenoff its chief medical officer and COO. Almenoff will lead the development of Innovate's pipeline including the upcoming phase 3 program for celiac disease.

* Blake Insomnia Therapeutics Inc. said its founder and CEO, Birger Jan Olsen, resigned from all officer positions and as a member of the board. The pharmaceutical company appointed Daniel Cattlin to serve as president, CEO and CFO.

* Mersana Therapeutics Inc. appointed David Spellman CFO.

* Assembly Biosciences Inc. appointed Graham Cooper CFO and COO. Cooper will be assuming the roles previously held by David Barrett, one of Assembly Biosciences' co-founders. Barrett will continue as a strategic adviser to the company.

* Syros Pharmaceuticals Inc. appointed Joseph Ferra CFO.

* Joanne Spadoro resigned as COO of T2 Biosystems Inc. Spadoro will continue to provide services as a consultant and transition to the company's scientific advisory board.

* Jonathan Poole resigned as CFO of Genocea Biosciences Inc. effective March 23. The company is conducting a search to replace Poole, and in the interim, President and CEO William Clark will assume the duties of principal financial officer and principal accounting officer.

Tayyeba Irum contributed to this article.